Clinical Trial Update: Phase II Study of Ridaforolimus (MK-8669) With Metastatic Bone or Soft-tissue Sarcoma Patients (MK-8669-030 AM1) [Phase 2]

View source ↗

Summary

This is a completed Phase II clinical trial evaluating ridaforolimus (MK-8669) in patients with metastatic bone cancer or soft-tissue sarcoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Cancer
• Soft Tissue Sarcoma

Drugs mentioned

• Ridaforolimus (ridaforolimus)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Sarcoma | Phase 2 | Status: COMPLETED